Dr. Rodney Ho, the Principal Investigator (PI) and Director of the Center for WE-REACH talked with USA Today, Salon, and Geekwire to discuss remdesivir, lopinavir, and hydrochloroquinine as potential treatments for Covid-19.
As part of the center’s focus on providing scientists a bridge to medical impact, WE-REACH has prepared a list of funding opportunities with the NIH. For additional opportunities, see WE-REACH partner ITHS.
Congress and US federal agencies have responded to the coronavirus threat with funding aimed at fast-tracking promising technologies and products that can help address the needs. Examples of recently funded projects include support of the first high-throughput COVID-19 diagnostic test from Hologic as well as tests from several other companies.
Medical Countermeasures BARDA Portal
BARDA has provided a single point of entry to government agencies that are looking for products and technologies to address the COVID-19 outbreak. Open to independent entities or teams from academic institutions, government labs and private sector organizations.
Required submission materials include a description of your product or technology, a slide deck, manuscript, publications, or other non-confidential information.
Agencies are looking for vaccines, diagnostics, therapeutics, and other products and services.
Broad Agency Announcement
Additional information about the program
BARDA and the Public Health Emergency
COVID-19 Research Supplements to Current NIH Grants and Cooperative Agreements
The National Heart, Lung, and Blood Institute (NHLBI) has issued a Notice of Special Interest in response to the urgent need for research on the Coronavirus 2019 and the biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Research interests include, but not limited to, host factors, manifestations, complications, time course of virus-host interactions, biological pathways, use of artificial intelligence to understand the COVID-19 pathways and comorbidities, antibody response, development of GMP quality hyperimmune globulin from patients who have recovered, and testing strategies.
|
|
|
Dr. Simone Perazzolo, a scientist in the TLC-ART Program, was featured on Italian national TV explaining how an FDA approved protease inhibitor called Lopinavir (Kaletra) may be effective against Covid-19 since requires protease enzymes to replicate.
He has highlighted targeted and long-acting drug combinations containing Lopinavir + Tenofovir (HIV and Hepatitis B drugs) currently in late-stage development for human testing by TLC-ART. This therapy may potentially replace 30-60 daily pills with a single injection. This product candidate was made possible by innovations in drug combination nano-particle technology (DcNP) discovered by the TLC-ART Program led by Drs. Rodney Ho and Ann Collier with the support of the NIH/NIAID, Division of AIDS (DAIDS).
Please follow the video link for the full interview.
Unitaid, a partner of the UW TLC-ART Program and a funding arm of the WHO, has announced for innovations in the development of fit-for-purpose oxygen therapy for global health and access. Depending on the scope of the project, the funding range is between USD 500k-2M. The deadline is March 19th, 2020. Please follow the link for details.